ClinicaliQ Trial Snapshot
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia — Recruiting • Phase II / Phase III • NCT07441876.
- Comparing two growth-boosting drugs (BMN 333 and vosoritide) in children with achondroplasia to see which works better and is safer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part. Conditions: Achondroplasia Interventions: BMN 333, Vosoritide Injection [Voxzogo] Lead Sponsor: BioMarin Pharmaceutical Planned Enrollment: 160 participants